NanoBio Corporation, a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform, today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.
“Given that cystic fibrosis patients are susceptible to respiratory failure following repeated bacterial infections of the lung, there is a tremendous need to develop new treatments that can overcome drug-resistant bacteria,” said James R. Baker, Jr., MD, NanoBio’s CEO and founder. “In laboratory studies, NB-401 is a very potent killer against these difficult strains.”
NB-401 has been shown to be highly efficacious in vitro against Pseudomonas aeruginosa, Burkholderia, Acinetobacter, Stenotrophomonas and other multidrug-resistant bacterial strains from cystic fibrosis (CF) patients, including colistin-resistant isolates of Burkholderia and Stenotrophomonas. In addition, the nanoemulsion is effective against organisms that are grown in biofilm and the sputum from CF patients. Resistance to the nanoemulsion is not anticipated based on its unique mechanism of action of interacting with the bacterial membrane and causing physical lysis of the organism.
These findings suggest that the use of NB-401 may have clinical benefit in treating CF patients. NanoBio has completed additional studies demonstrating that NB-401 can effectively be nebulized for the treatment of pulmonary infections. The company is currently conducting toxicity studies prior to advancing to clinical testing of NB-401 for the treatment of bacterial infections associated with cystic fibrosis.
Cystic fibrosis affects an estimated 30,000 individuals in the United States and a total of 70,000 people worldwide.
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.